ADTX

Aditxt Inc.

ADTX, USA

Aditxt, Inc., a commercial-stage company, discovers and develops products in the areas of immune health, precision health, population health, women's health, and neurologic health. The company develops AditxtScore that enable individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It also develops ADI-100 for skin grafting, psoriasis, type 1 diabetes, and multiple sclerosis. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Mountain View, California.

https://www.aditxt.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
ADTX
stock
ADTX

Critical Analysis: Addex Therapeutics (NASDAQ:ADXN) & Aditxt (NASDAQ:ADTX) Defense World

Read more →
ADTX
stock
ADTX

$ADTX stock is down 21% today. Here's what we see in our data. Quiver Quantitative

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$61

Analyst Picks

Strong Buy

0

Buy

1

Hold

0

Sell

0

Strong Sell

0

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

-0.01

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very High

310.96 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-203.78 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-313,443.05 %

Low ≤ 5%

High ≥ 15%

Investors

* Institutions hold a combined 0.79% of the total shares of Aditxt Inc.

1.

Virtu Financial LLC

(0.4175%)

since

2025/06/30

2.

HRT FINANCIAL LLC

(0.2704%)

since

2025/06/30

3.

Tower Research Capital LLC

(0.0809%)

since

2025/06/30

4.

Morgan Stanley - Brokerage Accounts

(0.0141%)

since

2025/06/30

5.

UBS Group AG

(0.0027%)

since

2025/06/30

6.

SBI Securities Co Ltd

(0.0018%)

since

2025/06/30

7.

IFP Advisors, LLC

(0.0008%)

since

2025/06/30

8.

Bank of America Corp

(0.0004%)

since

2025/06/30

9.

Advisor Group Holdings, Inc.

(0.0001%)

since

2025/06/30

10.

Group One Trading, LP

(0%)

since

2025/06/30

11.

Harwood Advisory Group, LLC

(0%)

since

2025/06/30

12.

JONES FINANCIAL COMPANIES LLLP

(0%)

since

2025/06/30

13.

Goldman Sachs Group Inc

(0%)

since

2025/03/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

No earnings data available.

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(0.5)
Defensive
Moderately Defensive(5.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Wide Moat Company(6.3)
GARP
Not Attractive for GARP(2.5)
Growth
Weak Growth Prospect(2.5)
Momentum
Moderate Momentum(5)
Net Net
Not Undervalued (Net-Net)(0.5)
Quality
Low Quality Business(2.5)
Value
Overpriced(2.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.